{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MORAb-003", "query": { "intervention": "MORAb-003" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MORAb-003&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T03:39:49.510Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05613088", "title": "A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Ovarian" ], "interventions": [ { "name": "MORAb-202", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin (PLD)", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 106, "start_date": "2023-02-01", "completion_date": "2025-09-10", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 10, "location_summary": "Sacramento, California • San Francisco, California • Whittier, California + 7 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05613088" }, { "nct_id": "NCT00849667", "title": "Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Farletuzumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Farletuzumab-matched placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1100, "start_date": "2009-04-16", "completion_date": "2013-04-12", "has_results": true, "last_update_posted_date": "2022-12-30", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849667" }, { "nct_id": "NCT01018563", "title": "An Open Label Extension Study of the Efficacy of MORAb-003", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer" ], "interventions": [ { "name": "MORAb-003", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2010-01-13", "completion_date": "2013-03-05", "has_results": true, "last_update_posted_date": "2021-12-08", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 2, "location_summary": "Chula Vista, California • San Antonio, Texas", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01018563" }, { "nct_id": "NCT00318370", "title": "Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Farletuzumab", "type": "DRUG" }, { "name": "Chemo Plus Far", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 58, "start_date": "2006-05", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2015-09-09", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 18, "location_summary": "San Diego, California • Indianapolis, Indiana • Covington, Louisiana + 15 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Covington", "state": "Louisiana" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Metarie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00318370" }, { "nct_id": "NCT01004380", "title": "Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epithelial Ovarian Cancer" ], "interventions": [ { "name": "Farletuzumab, Carboplatin, and PLD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2009-11", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2014-07-17", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Brightwaters, New York + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Brightwaters", "state": "New York" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Harlingen", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004380" }, { "nct_id": "NCT01218516", "title": "A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Lung" ], "interventions": [ { "name": "Farletuzumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2011-06-27", "completion_date": "2013-11-01", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 54, "location_summary": "Chandler, Arizona • Glendale, Arizona • Beverly Hills, California + 50 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Gilroy", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218516" }, { "nct_id": "NCT02289950", "title": "A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Sensitive Ovarian Cancer in First Relapse" ], "interventions": [ { "name": "Farletuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 332, "start_date": "2015-03-19", "completion_date": "2020-08-13", "has_results": true, "last_update_posted_date": "2021-09-02", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 35, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289950" }, { "nct_id": "NCT00738699", "title": "An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "MORAb-003 (farletuzumab)", "type": "DRUG" }, { "name": "0.9% Saline", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 415, "start_date": "2008-09", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2017-03-30", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 34, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738699" }, { "nct_id": "NCT04300556", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Farletuzumab ecteribulin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2020-08-06", "completion_date": "2030-08-08", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 24, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04300556" }, { "nct_id": "NCT05577715", "title": "A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "MORAb-202", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2022-11-14", "completion_date": "2024-08-12", "has_results": true, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-09-05T03:39:49.510Z", "location_count": 13, "location_summary": "Orange, California • Lone Tree, Colorado • Clermont, Florida + 10 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Clermont", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05577715" } ] }